[1] Kumar R, Anand U, Priyadarshi RN. Lymphatic dysfunction in advanced cirrhosis: Contextual perspective and clinical implications. World J Hepatol,2021, 13(3):300-314. [2] Bhardwaj R, Vaziri H, Gautam A, et al. Chylous ascites: A review of pathogenesis, diagnosis and treatment. J Clin Transl Hepatol,2018,6(1):105-113. [3] Nadolski GJ, Chauhan NR, Itkin M. Lymphangiography and lymphatic embolization for the treatment of refractory chylous ascites.Cardiovasc Intervent Radiol,2018, 41(3):415-423. [4] Zhou DX, Zhou HB, Wang Q, et al. The effectiveness of the treatment of octreotide on chylous ascites after liver cirrhosis. Dig Dis Sci,2009,54(8):1783-1788. [5] 刘揆亮,孙宇光,夏松,等. 肝硬化合并乳糜性腹水34例临床特点分析.中华消化杂志,2014,34(2):96-99. [6] 中华医学会肝病学分会.肝硬化诊治指南.实用肝脏病杂志,2019,22(6):770-786. [7] Santos E, Moussa AM. Chylous ascites and lymphoceles: Evaluation and interventions. Semin Intervent Radiol,2020,37(3):274-284. [8] Thaler MA, Bietenbeck A, Schulz C,et al. Establishment of triglyceride cut-off values to detect chylous ascites and pleural effusions. Clin Biochem, 2017, 50(3):134-138. [9] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗指南(2022年版). 中华肝脏病杂志,2022,30(4):367-388. [10] Ito K, Hachisu Y, Shibasaki M, et al. Liver cirrhosis and hepatocellular carcinoma diagnosed from chylothorax: A case report. Clin Pract, 2021, 11(3): 582-586. [11] de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - renewing consensus in portal hypertension. J Hepatol,2022,76(4):959-974. [12] Tsauo J, Shin JH, Han K, et al. Transjugular intrahepatic portosystemic shunt for the treatment of chylothorax and chylous ascites in cirrhosis: A case report and systematic review of the literature. J Vasc Interv Radiol,2016,27(1):112-116. [13] Khaliq MF, Noorani MM, Chowdhry M, et al. Transjugular intrahepatic portosystemic shunt (TIPS) in refractory transudative chylothorax due to liver cirrhosis. Case Rep Med,2020,2020: 2581040. [14] Rajesh S, George T, Philips CA, et al. Transjugular intrahepatic portosystemic shunt in cirrhosis: An exhaustive critical update. World J Gastroenterol, 2020,26(37):5561-5596. [15] Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. Gut,2021,70(1):9-29. [16] Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology,2021,74(2):1014-1048. [17] Liu CJ, Sun AX, Shi XY, et al. Cirrhosis-related chylous ascites successfully treated with splenic artery embolization. J Vasc Interv Radiol, 2016,27(11): 1739-1741. [18] Kojima M, Inoue M, Yamamoto S,et al. Successful treatment of hepatic lymphorrhea by percutaneous transhepatic lymphangiography followed by sclerotherapy using OK-432.Surg Case Rep,2019,5(1):203. [19] Tai E, Min A, Rajan DK. A single-center experience with percutaneous interventional management of refractory chylous ascites. Can AssocRadiol J,2021, 72(4):871-875. [20] Lizaola B, Bonder A, Trivedi HD, et al. Review article: the diagnostic approach and current management of chylous ascites. Aliment PharmacolTher,2017, 46(9):816-824. |